[go: up one dir, main page]

RU2000100940A - FILMED TABLET OF IMPROVED SAFETY FOR THE UPPER DEPARTMENTS OF THE GASTROINTESTINAL TRACT - Google Patents

FILMED TABLET OF IMPROVED SAFETY FOR THE UPPER DEPARTMENTS OF THE GASTROINTESTINAL TRACT

Info

Publication number
RU2000100940A
RU2000100940A RU2000100940/14A RU2000100940A RU2000100940A RU 2000100940 A RU2000100940 A RU 2000100940A RU 2000100940/14 A RU2000100940/14 A RU 2000100940/14A RU 2000100940 A RU2000100940 A RU 2000100940A RU 2000100940 A RU2000100940 A RU 2000100940A
Authority
RU
Russia
Prior art keywords
dosage form
form according
preceding paragraphs
active ingredient
specified
Prior art date
Application number
RU2000100940/14A
Other languages
Russian (ru)
Other versions
RU2193880C2 (en
Inventor
Ричард Джон ДАНСЕРО
Петрус Якобус БЕККЕР
Original Assignee
Дзе Проктер Энд Гэмбл Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Проктер Энд Гэмбл Компани filed Critical Дзе Проктер Энд Гэмбл Компани
Publication of RU2000100940A publication Critical patent/RU2000100940A/en
Application granted granted Critical
Publication of RU2193880C2 publication Critical patent/RU2193880C2/en

Links

Claims (10)

1. Новая пероральная лекарственная форма, подлежащая доставке в желудок, причем указанная лекарственная форма включает безопасное и эффективное количество активного ингредиента, выбранного из группы, включающей антибиотики тетрациклиновой группы, препараты железа, хинидин, нестероидные противовоспалительные средства, алпренолол, аскорбиновую кислоту, каптоприл, теофиллин, зидовудин, бисфосфонаты или их смеси и фармацевтически приемлемые наполнители, где указанная пероральная лекарственная форма характеризуется обычно овальной формой и пленочным покрытием для облегчения быстрого прохождения через пищевод и предупреждения раздражения в ротовой полости, преддверии рта, глотке и пищеводе.1. A new oral dosage form to be delivered to the stomach, said dosage form comprising a safe and effective amount of an active ingredient selected from the group consisting of tetracycline antibiotics, iron preparations, quinidine, non-steroidal anti-inflammatory drugs, alprenolol, ascorbic acid, captopril, theophylline , zidovudine, bisphosphonates or mixtures thereof and pharmaceutically acceptable excipients, wherein said oral dosage form is typically oval shaped oh and film coated to facilitate rapid passage through the esophagus and preventing irritation in the mouth, buccal cavity, pharynx and esophagus. 2. Лекарственная форма по п.1, где указанное пленочное покрытие растворимо при рН от 1,2 до 5. 2. The dosage form according to claim 1, where the specified film coating is soluble at a pH of from 1.2 to 5. 3. Лекарственная форма по п.1 или 2, где указанное пленочное покрытие выбрано из группы, включающей гидроксипропилметилцеллюлозу, гидроксипропилцеллюлозу, карбоксиметилцеллюлозу, метилцеллюлозу, этилцеллюлозу, полиакрилат, поливинилпирролидон или желатин или их смеси. 3. The dosage form according to claim 1 or 2, wherein said film coating is selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, polyacrylate, polyvinylpyrrolidone or gelatin, or mixtures thereof. 4. Лекарственная форма по любому из предыдущих пунктов, где указанная лекарственная форма обладает следующими размерами от 0,23 до 0,85 дюймов длиной, от 0,11 до 0,4 дюймов шириной и от 0,075 до 0,3 дюймов толщиной. 4. The dosage form according to any one of the preceding paragraphs, where the specified dosage form has the following dimensions from 0.23 to 0.85 inches long, from 0.11 to 0.4 inches wide and from 0.075 to 0.3 inches thick. 5. Лекарственная форма по любому из предыдущих пунктов, где указанная лекарственная форма имеет модифицированную овальную или каплевидную форму. 5. The dosage form according to any one of the preceding paragraphs, where the specified dosage form has a modified oval or teardrop shape. 6. Лекарственная форма по любому из предыдущих пунктов, где указанный активный ингредиент выбран из группы, включающей эмперонийбромид, доксициклин, препараты железа, хлорид калия, хинидин, нестероидные противовоспалительные средства, алпренолол, аскорбиновую кислоту, каптоприл, теофиллин, зидовудин, ризедронат, алендронат или памидронат или их смеси. 6. A dosage form according to any one of the preceding paragraphs, wherein said active ingredient is selected from the group consisting of emperonium bromide, doxycycline, iron preparations, potassium chloride, quinidine, non-steroidal anti-inflammatory drugs, alprenolol, ascorbic acid, captopril, theophylline, zidovudine, risedronate, alizedronate pamidronate or mixtures thereof. 7. Лекарственная форма по любому из предыдущих пунктов, где указанный активный ингредиент выбран из группы, включающей ризедронат, алендронат или памидронат. 7. A dosage form according to any one of the preceding paragraphs, wherein said active ingredient is selected from the group consisting of risedronate, alendronate or pamidronate. 8. Лекарственная форма по любому из предыдущих пунктов, где указанная лекарственная форма содержит ризедронат в количестве от 0,25% до 40% композиции. 8. The dosage form according to any one of the preceding paragraphs, where the specified dosage form contains risedronate in an amount of from 0.25% to 40% of the composition. 9. Новая пероральная лекарственная форма по любому из предыдущих пунктов, где указанная лекарственная форма является спрессованной таблеткой, включающей частицы активного ингредиента и фармацевтически приемлемые наполнители. 9. The new oral dosage form according to any one of the preceding paragraphs, where the specified dosage form is a compressed tablet comprising particles of the active ingredient and pharmaceutically acceptable excipients. 10. Новая пероральная лекарственная форма по любому из предыдущих пунктов, где указанные частицы активного ингредиента сами покрыты пленкой. 10. The new oral dosage form according to any one of the preceding paragraphs, where these particles of the active ingredient are themselves coated with a film.
RU2000100940/14A 1997-06-11 1998-06-08 Film-covered tablet of improved safety for upper departments of gastrointestinal tract RU2193880C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4930697P 1997-06-11 1997-06-11
US60/049,306 1997-06-11

Publications (2)

Publication Number Publication Date
RU2000100940A true RU2000100940A (en) 2001-10-20
RU2193880C2 RU2193880C2 (en) 2002-12-10

Family

ID=21959131

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000100940/14A RU2193880C2 (en) 1997-06-11 1998-06-08 Film-covered tablet of improved safety for upper departments of gastrointestinal tract

Country Status (29)

Country Link
US (4) US6165513A (en)
EP (1) EP0989848B1 (en)
JP (3) JP5093937B2 (en)
KR (1) KR100400053B1 (en)
CN (1) CN1274279A (en)
AR (1) AR027158A1 (en)
AT (1) ATE277606T1 (en)
AU (1) AU729912B2 (en)
BR (1) BR9810027A (en)
CA (1) CA2293815C (en)
CO (1) CO4940409A1 (en)
DE (1) DE69826660T2 (en)
DK (1) DK0989848T3 (en)
ES (1) ES2226128T3 (en)
HU (1) HUP0004625A1 (en)
IL (2) IL133405A0 (en)
MY (1) MY127526A (en)
NO (1) NO996116L (en)
NZ (1) NZ503946A (en)
PE (1) PE82999A1 (en)
PL (1) PL337813A1 (en)
PT (1) PT989848E (en)
RU (1) RU2193880C2 (en)
SG (1) SG108292A1 (en)
SK (1) SK284690B6 (en)
TR (1) TR200000111T2 (en)
TW (1) TW542725B (en)
WO (1) WO1998056360A2 (en)
ZA (1) ZA985010B (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5093937B2 (en) * 1997-06-11 2012-12-12 味の素株式会社 Film-coated tablets to increase the safety of the upper gastrointestinal tract
AR024462A1 (en) 1999-07-01 2002-10-02 Merck & Co Inc PHARMACEUTICAL TABLETS
PE20011061A1 (en) * 2000-02-01 2001-11-20 Procter & Gamble SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXY-ETHYLIDEN-1,1-BISPHOSPHONIC SODIUM ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE
USD459798S1 (en) 2001-03-26 2002-07-02 Aventis Pharma S.A. Pill tablet
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
DE10129674A1 (en) * 2001-06-20 2003-01-16 Lohmann Gmbh & Co Kg Hydrocolloid compositions and their use for the production of redispersible coatings, films, foils or papers
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
EP2172192A1 (en) 2001-12-24 2010-04-07 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder of granular material, and process and tooling for producing it
MXPA04010009A (en) * 2002-04-11 2005-07-01 Teva Pharma Novel polymorphs and pseudopolymorphs of risedronate sodium.
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
PL212072B1 (en) * 2002-12-20 2012-08-31 Hoffmann La Roche High dose ibandronate formulation
TR200300510A2 (en) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dispersing alendronate microparticle formulation
US7485319B2 (en) * 2003-07-25 2009-02-03 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form
WO2005023270A2 (en) * 2003-09-09 2005-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
RU2326695C2 (en) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Pharmaceutical formulations and methods including combinations of 2-alkyliden derivatives of 9-nor-vitamin d and bisphosphonate
WO2005046651A1 (en) * 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Liquid filled capsules of doxycycline
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
BRPI0510074A (en) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int pharmaceutical compositions for the treatment of sexual disorders ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8858960B2 (en) * 2004-11-19 2014-10-14 GlaxoSmithKline, LLC Method of producing a pharmaceutical product
US20070271153A1 (en) * 2004-12-23 2007-11-22 Amit Goel Method and system of aggregating listings for sale
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008538741A (en) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment and / or prevention of depression
EP1867324B1 (en) * 2005-03-31 2016-07-13 Takeda Pharmaceutical Company Limited Tablet
JP2008540356A (en) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Drug abuse treatment methods
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
JP2009503020A (en) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin in the treatment of obesity
JP2009513604A (en) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazolone derivatives for the treatment of premenstrual disorders and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US7964215B1 (en) * 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
KR20090005371A (en) * 2006-05-09 2009-01-13 베링거 인겔하임 인터내셔날 게엠베하 Use of Plyvanserine for the Treatment of Postmenopausal Sexual Disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
MX2009001551A (en) * 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulations of flibanserin and method for manufacturing the same.
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
WO2008022932A2 (en) * 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
JP5676834B2 (en) * 2006-11-29 2015-02-25 エスエス製薬株式会社 Oral solid composition with reduced irritation to the gastrointestinal tract
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
JP5441354B2 (en) * 2007-05-23 2014-03-12 キヤノン株式会社 Ink set, ink jet recording method, ink cartridge, and ink jet recording apparatus
WO2009018834A1 (en) * 2007-08-06 2009-02-12 Pharmathen S.A. Pharmaceutical composition containing bisphosphonate and method for the preparation thereof
UY31335A1 (en) * 2007-09-12 2009-04-30 VASOMOTOR SYMPTOMS TREATMENT
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
PL2459176T3 (en) 2009-07-31 2018-02-28 Grünenthal GmbH Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
MX390695B (en) * 2010-09-21 2025-03-21 Intekrin Therapeutics Inc Antidiabetic solid pharmaceutical compositions
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
WO2013015599A2 (en) * 2011-07-28 2013-01-31 Yuhan Corporation Pharmaceutical composition for oral administration comprising bisphosphonic acid or its salt
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CN105263482A (en) * 2013-04-05 2016-01-20 努梅迪公司 Treatment of gastrointestinal and other disorders
AU2015299105B2 (en) * 2014-08-04 2020-10-29 Dbv Technologies Compositions of food allergens
USD787042S1 (en) * 2015-04-28 2017-05-16 Celgene Corporation Pharmaceutical tablet
USD787043S1 (en) * 2015-06-23 2017-05-16 Celgene Corporation Pharmaceutical tablet
USD816506S1 (en) 2015-11-02 2018-05-01 Pura Scents, Inc. Vial for a scent dispenser
USD809116S1 (en) 2015-11-02 2018-01-30 Pura Scents Dispenser
CA3133723C (en) 2015-11-02 2023-06-27 Pura Scents, Inc. Scent dispensation
US10314514B2 (en) * 2016-05-29 2019-06-11 Ankon Medical Technologies (Shanghai) Co., Ltd. System and method for using a capsule device
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
WO2018029565A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition
USD813372S1 (en) 2017-02-22 2018-03-20 Celgene Corporation Pharmaceutical tablet
USD835257S1 (en) 2017-02-22 2018-12-04 Celgene Corporation Pharmaceutical tablet
USD906513S1 (en) 2019-03-19 2020-12-29 Novo Nordisk A/S Pill

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161530A (en) * 1975-01-06 1979-07-17 Ciba-Geigy Corporation Pharmaceutical combination preparations as hypnotics
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
ES1000119Y (en) * 1986-02-24 1988-06-01 Smithkline Beckman Corporation A PHARMACEUTICAL TABLET FOR ORAL ADMINISTRATION
IE69270B1 (en) * 1989-01-03 1996-08-21 Sterling Winthrop Inc Controlled-release low-dose aspirin
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
FR2738833B1 (en) * 1995-09-14 1997-12-05 Seppic Sa FILM-FORMING COMPOSITION FOR THE MASKING OF TASTE FOR THE COATING OF INGEABLE SOLID FORMS SUCH AS IN PARTICULAR PHARMACEUTICAL TABLETS
DE19615812A1 (en) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmaceutical preparation containing diphosphonic acids for oral administration
JP5093937B2 (en) * 1997-06-11 2012-12-12 味の素株式会社 Film-coated tablets to increase the safety of the upper gastrointestinal tract
JPH11246392A (en) * 1998-03-03 1999-09-14 Makoto Otsuka Oral solid formulation

Similar Documents

Publication Publication Date Title
RU2000100940A (en) FILMED TABLET OF IMPROVED SAFETY FOR THE UPPER DEPARTMENTS OF THE GASTROINTESTINAL TRACT
SG108292A1 (en) Film-coated tablet for improved upper gastrointestinal tract safety
NO932979L (en) ORAL DOSAGE FORMS WITH DELAYED DELIVERY FOR TREATMENT OF GAS TURNS
DE69231313D1 (en) Medicines containing risedronate with delayed drug delivery
CA2453263A1 (en) Pharmaceutical compositions containing terbinafine and use thereof
TH31107B (en) Film-coated tablets for improved safety for the upper gastrointestinal tract.
TH61079A (en) Film-coated tablets for improved safety for the upper gastrointestinal tract.
Tabata et al. Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)